Pharma has long battled with demonstrating its value to society, tightly holding on to the innovation story as a key channel of communicating its worth to stakeholders in health and care. The trouble ...

With another year almost gone it’s time once again to look back at how the pharma and healthcare industries have fared over the last 12 months. Despite a lot of upheaval last year, it’s clear that ...

The autoimmune disease, which affects 1.5 million people in the US, causes the body's immune system to attack its own tissues Researchers from Johns Hopkins Medicine have revealed that certain ...

The aggressive brain cancer is responsible for over 3,000 cases in the UK every year Researchers from King’s College London (KCL) have developed an artificial intelligence (AI)-based model that can ...

Researchers at Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge have announced the launch of the BEST4 trial to evaluate a capsule sponge test to prevent oesophageal ...

The therapy has been developed for the treatment of migraine among adults The therapy has been developed for the treatment of migraine among adults AbbVie has revealed that the Medicines and ...

The development is part of company’s mission to support patient access to clinical trials The development is part of company’s mission to support patient access to clinical trials Innovative Trials – ...

Jeff Elton, chief executive of ConcertAI, talks to PharmaTimes about the pandemic’s impact on oncology trials in the US ...

The misuse and overuse of antibiotics has consequences. We are in very real danger of creating an environment where chemotherapy is unsafe, pneumonia becomes untreatable and a simple cut can kill. The ...

The University of Exeter and Medicines Discovery Catapult (MDC) have partnered to accelerate medicines research and development to maximise the impact and value of basic medical research. The ...

Subcutaneous formulation of Darzalex in combination with pomalidomide and dexamethasone meets primary endpoint Genmab and Janssen’s subcutaneous formulation of Darzalex (daratumumab) in combination ...